---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023344"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:08:30.898219+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs Q2 net loss narrows to $4.5M, gross margin turns positive; patent for BE-Smart; crypto treasury approved

## Summary
- Q2 revenue $1.2M vs $1.5M YoY; net loss from continuing ops $4.5M ($0.11/share) vs $5.5M ($0.29/share).
- Gross margin improved to 58.9% from (10.3)% YoY; operating expenses cut 35% YTD; sale of PMI generated $8.7M gain.
- U.S. patent granted for BE-Smart esophageal adenocarcinoma test in August 2025; accelerates commercialization.
- Board approved crypto treasury strategy including Bitcoin; proposed authorized share increase to 1 billion for flexibility.
- Stockholders' equity rose to $11.5M (from $7.4M at year-end); cash $169K; Crown Medical estimates $50M recovery.

## SEC filing metadata
- accession: 0001641172-25-023344
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000164117225023344/0001641172-25-023344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000164117225023344/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023344
- JSON: https://secwatch.observer/filing/0001641172-25-023344.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.